natgillin/translations-raw huggingface dataset:
The reconstituted vaccine is a homogeneous white emulsion.
Rekonstituirano cjepivo je homogena, bijela emulzija.
The reconstituted vaccine is a transparent to opaque white-yellowish suspension depending on the volume of water used for dilution.
Razrijeđeno cjepivo je prozirna do prozirna bijelo-žuta suspenzija ovisno o volumenu vode korištene za otapanje.
The reconstituted vaccine is slightly more turbid than the solvent and is milky white in appearance.
Rekonstituirano cjepivo je nešto mutnije nego otapalo i mliječnobijele je boje.
The reconstituted vaccine is slightly more turbid than the solvent and is milky white in appearance.
Rekonstituirano cjepivo je nešto mutnije od samog otapala i mliječnobijele je boje.
The reconstituted vaccine is transparent to opaque white-yellowish suspension depending on the volume of water used for dilution.
Razrijeđeno cjepivo je prozirna do prozirna bijelo-žuta suspenzija ovisno o volumenu vode korištene za otapanje
The reconstituted vaccine should be inspected visually for any foreign particulate matter and/or abnormal physical appearance prior to administration.
Prije primjene, rekonstituirano cjepivo treba vizualno pregledati da ne sadrži strane čestice i/ili da nema neuobičajen izgled.
The reconstituted vaccine should be inspected visually for any foreign particulate matter and/or variation of physical aspect prior to administration.
Prije primjene, pripremljeno cjepivo treba pregledati na prisutnost stranih čestica i/ili promjenu izgleda.
The reconstituted vial should be used immediately.
Rekonstituirana bočica se mora odmah upotrijebiti.
The reconstituted vial with 10 mL of 0.9% sodium chloride (normal saline) for injection contains 11.5 mmol (265 mg) of sodium.
Bočica rekonstituirana s 10 ml 0,9%-tne otopine natrijevog klorida (normalna fiziološka otopina) za injekciju sadrži 11,5 mmol (265 mg) natrija.
The reconstituted vial with 10 mL of 0.9% sodium chloride (normal saline) for injection contains 11.5 mmol (265 mg) of sodium.
Sadržaj bočice rekonstituiran s 10 ml 0,9%-tne otopine natrijevog klorida (fiziološke otopine) za injekciju sadrži 11,5 mmol (265 mg) natrija.
The reconstituted vials and/or diluted intravenous bags may be stored for a cumulative time of up to 24 hours in a refrigerator (2°C – 8°C).
Bočice s rekonstituiranim lijekom i/ili infuzijske vrećice s razrijeđenim lijekom mogu se čuvati tijekom ukupno 24 sata u hladnjaku (2°C – 8°C).
The reconstituted volume allows accurate withdrawal of 10.0 ml (equal to 400 units) from each vial.
Volumen rekonstituirane otopine omogućuje uzimanje točno 10,0 ml (što odgovara 400 jedinica) otopine iz svake bočice.
The reconstituted volume allows accurate withdrawal of 5.0 ml (equal to 200 units) from each vial.
Volumen rekonstituirane otopine omogućuje uzimanje točno 5,0 ml (što odgovara 200 jedinica) otopine iz svake bočice.
The reconstituted volume is 10.5 ml containing 5 mg enzyme/ml, and appears as a clear, colourless to pale yellow solution which may contain particles in the form of thin white strands or translucent fibres.
Rekonstituirani volumen od 10,5 ml sadrži 5 mg/ml lijeka i bistra je bezbojna do blijedožuta otopina koja može sadržavati čestice u obliku tankih bijelih niti ili prozirnih vlakana.
The reconstituted, filtered and diluted suspension for infusion is a homogenous, white to off-white, opaque liposomal suspension, free of visible particles and free of foam and lipid lumps.
Rekonstituirana, profiltrirana i razrijeđena suspenzija za infuziju je homogena, bijela do bjeličasta, mutna liposomalna suspenzija, bez vidljivih čestica te bez pjene i nakupina lipida.
The Reconstitution poster shall contain the following key elements: different reconstitution requirements for Bortezomib Accord 3.5 mg IV or SC use
Poster s uputstvima za rekonstituciju lijeka sadržavati će sljedeće ključne elemente: različite zahtjeve kod pripreme Bortezomib Accorda 3,5 mg za i.v. ili s.c. put primjene
The Reconstitution poster shall contain the following key elements: different reconstitution requirements for Bortezomib Hospira 3.5 mg IV or SC use
Poster s uputstvima za rekonstituciju lijeka sadržavati će sljedeće ključne elemente: različite zahtjeve kod pripreme Bortezomib Hospira 3,5 mg za i.v. ili s.c. put primjene
The Reconstitution poster shall contain the following key elements: different reconstitution requirements for Bortezomib SUN 3.5 mg IV or SC use
Poster s uputstvima za rekonstituciju lijeka sadržavati će sljedeće ključne elemente: različite zahtjeve kod pripreme Bortezomib SUN-a 3,5 mg za i.v. ili s.c. put primjene
The Reconstitution poster shall contain the following key elements: different reconstitution requirements for VELCADE 3.5 mg IV or SC use
Poster s uputstvima za rekonstituciju lijeka sadržavati će sljedeće ključne elemente: različite zahtjeve kod pripreme VELCADEa 3,5 mg za i.v. ili s.c. put primjene
The reconstitution time can be up to 5 mins.
Priprema može trajati do 5 minuta.
The recovery of hypoglycaemia may be delayed because Toujeo has a long action.
Oporavak od hipoglikemije može potrajati jer Toujeo ima dugotrajno djelovanje.
The recovery of the total radioactivity in faeces and urine following administration of 14C-tigecycline indicates that 59 % of the dose is eliminated by biliary/faecal excretion, and 33 % is excreted in urine.
Ukupna radioaktivnost koju je moguće pronaći u stolici i urinu nakon primjene 14C-tigeciklina pokazuje da se 59% doze eliminira izlučivanjem putem žuči/stolice, dok se 33% izlučuje u urinu.
The recurrence day was the visit where the recurrence was reported or the day of intervention if a joint was treated for a worsening Dupuytren's contracture.
Dan recidiva je dan posjeta na kojem je zabilježen recidiv ili dan intervencije ako je zglob liječen zbog pogoršanja Dupuytrenove kontrakture.
The reduced dose and/or
Everolimus
The reduced doses for patients with renal impairment are expected to achieve the same AUC as that seen in patients with creatinine clearance of 75 ml/min.
Očekuje se da će smanjena doza u bolesnika s bubrežnim oštećenjem postići isti AUC kao onaj u bolesnika s klirensom kreatinina od 75 ml/min.
The reduced doses for patients with renal impairment are expected to achieve the same AUC as that seen in patients with creatinine clearance of 75 ml/min.
Očekuje se da će snižene doze u bolesnika s oštećenjem funkcije bubrega postići isti AUC kakav se opaža u bolesnika s klirensom kreatinina od 75 ml/min
the reduced loperamide plasma
plazmi su se značajno povisile, dok
The reduced risk of cardiotoxicity has also been shown in a retrospective analysis in patients who had received prior adjuvant doxorubicin (log-rank P=0.001, Hazard Ratio=5.42).
Smanjeni rizik od kardiotoksičnosti također je pokazala retrospektivna analiza bolesnika koji su prethodno adjuvantno liječeni doksorubicinom (log-rang P = 0,001, omjer rizika = 5,42).
The reduction from baseline in mean DAS28 score at day 365 (- 3.06) was maintained through day 729 (-3.34) in those patients who continued with abatacept.
Smanjenje prosječnog DAS28 rezultata 365. dana u odnosu na početne vrijednosti (-3,06) održalo se do 729. dana (-3,34) u onih bolesnika koji su nastavili primati abatacept.
The reduction in B-CAP and C-CAP was greatest in children < 36 months of age (vaccine efficacy of 20.6% (95% CI: 6.5; 32.6) and 24.2% (95% CI: 7.4; 38.0) respectively).
Smanjenje pojave B-CAP odnosno C-CAP bilo je najveće u djece u dobi < 36 mjeseci (djelotvornost cjepiva iznosila je 20,6% (95% CI: 6,5; 32,6) odnosno 24,2% (95% CI: 7,4; 38,0)).
The reduction in diastolic blood pressure <90 mmHg was achieved in 71.6 %, 74.8 %, 82.1 %, 85.3 % of patients respectively.
Sniženje dijastoličkog krvnog tlaka <90 mmHg bilo je postignuto kod 71,6%, 74,8%, 82,1%, 85,3% bolesnika, po istom redoslijedu.
The reduction in HbA1c in patients treated with sitagliptin and insulin (with or without metformin) was -1.31 % compared to -0.87 % in patients treated with placebo and insulin (with or without metformin), a difference of -0.45 % [95 % CI: -0.60, -0.29].
Sniženje vrijednosti HbA1c u bolesnika liječenih sitagliptinom i inzulinom (s metforminom ili bez njega) iznosilo je -1,31% u usporedbi s -0,87% u bolesnika koji su liječeni placebom i inzulinom (s metforminom ili bez njega), što predstavlja razliku od -0,45% [95 % CI: -0,60; -0,29].
The reduction in HbA1c levels (in percentage points) was 0.7 in patients with type 1 diabetes and between 1 and 1.7 across the trials in patients with type 2 diabetes.
Smanjenje razina HbA1c (u postocima) iznosilo je 0,7 u bolesnika sa šećernom bolesti tipa 1 i između 1 i 1,7 u ispitivanjima provedenima na bolesnicima sa šećernom bolesti tipa 2.
The reduction in HbA1c was sustained and the weight loss continued for at least 82 weeks in the subset of 10 mcg BID patients completing both the placebo-controlled studies and the uncontrolled study extensions (n=137).
Sniženje HbA1c se održalo, a gubitak težine nastavio tijekom najmanje 82 tjedna u podskupini bolesnika liječenih dozom od 10 µg dvaput na dan koji su dovršili i placebom kontrolirana ispitivanja i nekontrolirane produžetke ispitivanja (n=137).
The reduction in incidence of colectomy was also examined in another randomised, double-blind study (C0168Y06) in hospitalised patients (n = 45) with moderately to severely active ulcerative colitis who failed to respond to IV corticosteroids and who were therefore at higher risk for colectomy.
Smanjena incidencija kolektomije ispitivana je i u drugom randomiziranom, dvostruko slijepom kliničkom ispitivanju (C0168Y06) u hospitaliziranih bolesnika (n = 45) sa umjerenim do teškim, aktivnim ulceroznim kolitisom koji nisu odgovorili na liječenje i.v. kortikosteroidima i koji su stoga imali veći rizik za kolektomiju.
The reduction in incidence of colectomy was also examined in another randomised, double-blind study (C0168Y06) in hospitalised patients (n=45) with moderately to severely active ulcerative colitis who failed to respond to intravenous (IV) corticosteroids and who were therefore at higher risk for colectomy.
Smanjena incidencija kolektomije ispitivana je i u drugom randomiziranom, dvostruko slijepom kliničkom ispitivanju (C0168Y06) u hospitaliziranih bolesnika (n = 45) s umjerenim do teškim, aktivnim ulceroznim kolitisom koji nisu odgovorili na liječenje intravenskim (i.v.) kortikosteroidima i koji su stoga imali veći rizik za kolektomiju.
The reduction in incidence of colectomy was also examined in another randomised, double-blind study (C0168Y06) in hospitalised patients (n=45) with moderately to severely active ulcerative colitis who failed to respond to IV corticosteroids and who were therefore at higher risk for colectomy.
Smanjena incidencija kolektomije ispitivana je i u drugom randomiziranom, dvostruko slijepom kliničkom ispitivanju (C0168Y06) u hospitaliziranih bolesnika (n = 45) s umjerenim do teškim, aktivnim ulceroznim kolitisom koji nisu odgovorili na liječenje i.v. kortikosteroidima i koji su stoga imali veći rizik za kolektomiju.
The reduction in risk for a vomiting episode over the 0 to 24 hour period with aprepitant 40 mg relative to ondansetron 4 mg was 53.3 % (95 % C.I.: 35.3 to 66.3) in an analysis that censors patients at the time of rescue use.
Smanjenje rizika za nastup epizode povraćanja u razdoblju od 0 do 24 sata nakon operacije bilo je 53,3% kod primjene aprepitanta 40 mg u odnosu na ondanzetron 4 mg (95% CI: 35,3 do 66,3) u analizi koja isključuje bolesnike koji su uzeli dodatni lijek za olakšanje simptoma.
The reduction in severe asthma attacks and consequent need for hospital treatment was considered important and outweighed the low risk of side effects, since the medicine’s safety profile raised no major concerns.
Smanjenje broja teških napadaja astme i posljedična potreba za bolničkim liječenjem smatrani su važnima te su nadmašili nizak rizik od nuspojava, jer sigurnosni profil lijeka nije predstavljao veće bojazni.
The reduction in the incidence of new vertebral fractures, hip fractures and non-vertebral fractures by Prolia over 3 years were consistent regardless of the 10-year baseline fracture risk.
Smanjenje incidencije novih fraktura kralježnice i kuka te nevertebralnih fraktura uzimanjem lijeka Prolia tijekom 3 godine je bilo konzistentno, neovisno o inicijalnom desetogodišnjem riziku za frakturu.
The reduction of bupropion plasma levels is likely due to induction of CYP2B6 and UGT activity by RTV
Sniženje vrijednosti bupropiona u plazmi javlja se vjerojatno zbog indukcije aktivnosti CYP2B6 i UGT ritonavirom
The reductions from baseline in HbA1c respectively for saxagliptin and sitagliptin in the primary per-protocol analysis were -0.5% (mean and median) and
Smanjenja HbA1c u odnosu na početne vrijednosti za saksagliptin i sitagliptin u osnovnim analizama prema planu ispitivanja iznosile su
the reductions in etravirine
farmakokinetičkih
the reductions in etravirine
kontracepcijskih sredstava na
the reductions in etravirine
redukcijefarmakokinetičkih
The reductions in HbA1c and superiority vs sitagliptin observed after 26 weeks of liraglutide treatment (1.2 mg and 1.8 mg) were sustained after 52 weeks of treatment (­1.29% and ­1.51% vs ­0.88%, p0.0001).
Smanjenje HbA1c i superiornost naspram sitagliptina opažena nakon 26 tjedana liječenja liraglutidom (1,2 mg i 1,8 mg) zadržala se i nakon 52 tjedna liječenja (-1,29% i -1,51% naspram -0,88%, p<0,0001).
The reductions in RTG and increases in UGE were sustained over a 26-week dosing period in patients with type 2 diabetes.
Smanjenja RTG i povišenja UGE zadržala su se kroz 26-tjedno razdoblje doziranja u bolesnika s dijabetesom tipa 2.
The reductions in RTG led to increased UGE in subjects with type 2 diabetes treated with either 100 mg or 300 mg of canagliflozin ranging from 77 g/day to 119 g/day across the phase 1 studies; the UGE observed translates to a loss of
Smanjenja RTG dovela su do povišenog UGE u ispitanika s dijabetesom tipa 2 liječenih bilo sa 100 mg ili 300 mg kanagliflozina u rasponu od 77 g/dan do 119 g/ dan kroz ispitivanja faze 1; uočen UGE prevodi se na gubitak 308 kcal/dan do
The reference medicine for Abasaglar is Lantus.
Referentni lijek za Abasaglar je lijek Lantus.
The reference medicine for Abseamed is Eprex/Erypo.
Referentni lijek za Abseamed je Eprex/Erypo.
The reference medicine for Bemfola is GONAL-f.
Referentni lijek za lijek Bemfola je GONAL-f.
The reference medicine for Binocrit is Eprex/Erypo.
Referentni lijek za Binocrit je Eprex/Erypo.
The reference medicine for Budesonide/Formoterol Teva is Symbicort Turbohaler.
Referentni lijek za Budesonide/Formoterol Teva je Symbicort Turbohaler.
The reference medicine for Ovaleap is GONAL-f.
Referentni lijek za Ovaleap je GONAL-f.
The reference medicine for Remsima is Remicade.
Referentni lijek za lijek Remsima je Remicade.
The refrigerated solution should then be equilibrated to room temperature prior to administration.
Prije primjene rashlađenu otopinu treba pustiti da dosegne sobnu temperaturu.
The regimen 3 mg/kg/day during 6 months (selected at the end of the phase II part of the study) presented 60.4% of success versus 3.6% in the placebo arm (p value < 0.0001).
Režim 3 mg/kg/dnevno tijekom 6 mjeseci (odabran na kraju II faze studije) pokazao je 60,4% uspješnosti u odnosu na 3,6% uspješnosti na placebu studije (p-vrijednost <0,0001).
The regimen administered should be selected based on the anticipated efficacy and safety of the combination treatment for an individual patient (see section 5.1).
Terapijsku kombinaciju treba odabrati na temelju očekivane djelotvornosti i sigurnosti kombinacije za pojedinog bolesnika (vidjeti dio 5.1).
The registry is planned to be continued until at least 70 patients are recruited on Firdapse and followed for up to five years, with a minimum of at least three years for the last subject recruited to the registry.
Planira se nastaviti s registrom sve dok se najmanje 70 pacijenata ne uključi u liječenje lijekom Firdapse i prati do pet godina, a najmanje tri godine nakon uključenja zadnjeg ispitanika u registar.
The registry should be
Registar je
The registry will monitor accumulating data on efficacy and safety in the treatment of inborn errors in primary bile acid synthesis in infants, children, adolescents and adults due to Sterol 27-hydroxylase (presenting as cerebrotendinous xanthomatosis, CTX), 2- (or α-) methylacyl-CoA racemase (AMACR) and Cholesterol 7α- hydroxylase (CYP7A1) deficiencies.
Registar će pratiti prispjele podatke o djelotvornosti i sigurnosti u liječenju prirođenih grešaka u sintezi primarne žučne kiseline u dojenčadi, djece, adolescenata i odraslih osoba zbog manjkavosti sterol 27-hidroksilaze (manifestira se kao cerebrotendinozna ksantomatoza, CTX), 2- (ili α-) metilacil-CoA racemaze (AMACR) i kolesterol 7α-hidroksilaze (CYP7A1).
The reinstitution or withholding of Bronchitol following smaller episodes of haemoptysis should be based on clinical judgement.
Ponovno uvođenje ili prekid primjene Bronchitola nakon manjih epizoda hemoptize treba se temeljiti na kliničkoj procjeni.
The relapse rate was around 15%, and similar for patients with Child-Pugh A, B and C. The programmes do not allow for a direct comparison of efficacy between the 12- and 24-week regimens.
Stopa relapsa je bila oko 15%, i slično u bolesnika s Child-Pugh stadijem A, B i C. Programi ne dozvoljavaju direktnu usporedbu djelotvornosti 12 tjednog i 24 tjednog režima liječenja.
The relationship between rivaroxaban concentration and factor Xa activity was best described by an Emax model.
Odnos između koncentracije rivaroksabana i aktivnosti faktora Xa najbolje se može opisati modelom Emax.
The relationship between tacrolimus trough levels (C24) and systemic exposure (AUC0-24) for Envarsus is similar to that of immediate- release tacrolimus.
Odnos između najnižih izmjerenih doza takrolimusa (C24) i sustavne izloženosti (AUC0-24) za Envarsus sličan je onome za takrolimus s trenutnim oslobađanjem.
The relationship to Thyrogen administration is unknown.
Nije poznata povezanost s primjenom lijeka Thyrogen.
The relationship, if any, between receptor tyrosine kinase (RTK) inhibition and cardiac function remains unclear.
Ako uopće postoji, povezanost između inhibicije receptorske tirozin kinaze i poremećaja srčane funkcije ostaje nejasna.
The relative bioavailability is about 125% as compared to immediate-release cysteamine.
Relativna bioraspoloživost je oko 125% u usporedbi s cisteaminom s trenutačnim oslobađanjem.
The relative bioavailability of nevirapine when dosed as one 400 mg Viramune prolonged-release tablet, relative to two 200 mg Viramune immediate- release tablets, was approximately 75 %.
Relativna bioraspoloživost nevirapina pri dozi od jedne 400 mg Viramune tablete s produljenim oslobađanjem, u odnosu na dvije 200 mg Viramune tablete s trenutnim oslobađanjem, bila je oko 75 %.
The relative bioavailability of tocofersolan tended to be higher (Frel of 1.01 ± 1.74) with AUC0-t of 0.383 ± 0.203µM.h/mg, Cmax of 0.013 ± 0.006, tmax of 6.0 h (6.0 – 24.0), and t1/2 of 29.7 h (16.0 – 59.5).
Relativna bioraspoloživost tokofersolana naginjala je višim vrijednostima (Frel 1.01 ± 1.74) s AUC0-t 0.383 ± 0.203 µM.h/mg, Cmax 0.013 ± 0.006, tmax 6.0 h (6.0 – 24.0), te t1/2 29.7 h (16.0 – 59.5).
The relative contribution of BLyS levels to the pathophysiology of SLE is not fully understood.
Relativni doprinos razina BLyS patofiziologiji samog SLE nije u potpunosti razjašnjen.
The relative contribution of the inhibitors to inactivation of reteplase decreases as follows: C1-inactivator > 2- antiplasmin > 2-antitrypsin.
Relativni udio inhibitora u inaktivaciji reteplaze smanjuje se na sljedeći način: C1-inaktivator > 2- antiplazmin > 2-antitripsin.
The relative contributions of previous placebo treatment in the double-blind phase and of other medications started during the open- label extension period are unknown.
Nisu poznati relativni doprinosi prethodnog liječenja placebom u dvostruko slijepoj fazi ispitivanja i drugih lijekova koje se počelo uzimati tijekom otvorenog perioda produžetka liječenja.
The relative deficiency of TNFα caused by anti-TNF therapy may result in the initiation of an autoimmune process.
Relativni nedostatak TNFα prouzročeno anti-TNF terapijom može pokrenuti autoimuni proces.
The relative differences in the pharmacodynamic properties (GIRmax,AUCGIR, 0-120 min) between insulin aspart and human insulin in the elderly were similar to those seen in healthy subjects and in younger patients with diabetes.
Relativne razlike u farmakodinamičkim svojstvima (GIRmax, AUCGIR, 0-120 min) između aspart inzulina i humanog inzulina u starijih bolesnika bile su slične onima u zdravih ispitanika te u mlađih bolesnika sa šećernom bolešću.
The relative rate of ADPKD-related events was decreased by 13.5% in tolvaptan-treated patients, (hazard ratio, 0.87; 95% CI, 0.78 to 0.97; p=0.0095).
Relativna stopa događaja povezanih s ADPBB-om bila je snižena za 13,5% u bolesnika liječenih tolvaptanom (omjer hazarda 0,87; 95% CI od 0,78 do 0,97; p=0,0095).
The relative rate reduction indicates how much the incidence of IPD in children of ≤5 years of age was reduced in the Synflorix cohort (followed for 3 years after NIP introduction) versus age and season matched non-vaccinated historical cohorts (each followed for 3 year periods before introduction of Synflorix into NIP).
Relativna stopa smanjenja upućuje koliko je bila smanjena incidencija IPB-a u djece u dobi ≤5 godina u kohorti koja je primila Synflorix (praćena tijekom 3 godine nakon uvođenja NPI-a) naspram, prema dobi i sezoni usklađenim, necijepljenim povijesnim kohortama (svaka je praćena u razdoblju od 3 godine prije uvođenja cjepiva Synflorix u NPI).
The relative selectivity of vernakalant on atrial versus ventricular refractoriness is postulated to result from the block of currents that are expressed in the atria, but not in the ventricles, as well as the unique electrophysiologic condition of the fibrillating atria.
Pretpostavlja se da je relativna selektivnost vernakalanta na refrakternost atrija, naspram djelovanja na refrakternost ventrikula, posljedica blokade protoka iona koji su izraženi u atrijima, ali ne i u ventrikulima, kao i jedinstvenog elektrofiziološkog stanja atrija tijekom fibrilacije.
The relative treatment effect of ALIMTA was internally consistent across subgroups (including disease stage, induction response, ECOG PS, smoking status, gender, histology and age) and similar to that observed in the unadjusted OS and PFS analyses.
Relativan učinak liječenja lijekom ALIMTA bio je konzistentan u svim podskupinama (uključujući podskupine prema stadiju bolesti, odgovoru na uvodno liječenje, ECOG izvedbeni status, pušački status, spol, histološki tip tumora i dob) te podjednak onome opaženom u nekorigiranim analizama OS-a i PFS-a.
The relative treatment effect of pemetrexed was internally consistent across subgroups (including disease stage, induction response, ECOG PS, smoking status, gender, histology and age) and similar to that observed in the unadjusted OS and PFS analyses.
Relativan učinak liječenja pemetrekseda bio je konzistentan u svim podskupinama (uključujući podskupine prema stadiju bolesti, odgovoru na uvodno liječenje, ECOG izvedbeni status, pušački status, spol, histološki tip tumora i dob) te podjednak onome opaženom u nekorigiranim analizama OS-a i PFS-a.
The relative treatment effect of pemetrexed was internally consistent across subgroups (including disease stage, induction response, ECOG PS, smoking status, gender, histology and age) and similar to that observed in the unadjusted OS and PFS analyses.
Relativan učinak liječenja pemetreksedom bio je konzistentan u svim podskupinama (uključujući podskupine prema stadiju bolesti, odgovoru na uvodno liječenje, ECOG izvedbeni status, pušački status, spol, histologiju i dob) te podjednak onome opaženom u nekorigiranim analizama OS-a i PFS
The release liner is removed prior to application.
Prije primjene uklanja se zaštitna podloga.
The release liner should NOT be removed until just prior to application.
Zaštitnu foliju NE treba ukloniti sve do neposredne primjene.